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Chimeric primate lentiviruses composed of SIV and HIV genes may allow the analysis of the role of these discrete HIV
genes in viral pathogenesis in macaque monkeys. We have constructed a chimeric virus in which the env, rev, tat, and vpu
genes of HIV-1 Lai replace the env, rev, and tat genes of the SIVmac239 genome. This virus, SHIVsbg, replicates efficiently
in rhesus (Indian and Chinese subspecies) and cynomolgus monkeys with viral loads in PBMC and lymph nodes of up to
one infected cell per 30 cells during the acute phase of the infection. Sera from all monkeys recognize specific HIV-1
glycoproteins. The onset of lymphadenopathy in all animals was concurrent with a depletion of CD4 lymphocytes in peripheral
blood. The virulence of this SHIV for rhesus and cynomolgus monkeys therefore closely parallels that of HIV-1 for human
in the acute phase of the infection. Changes in the env and vpu genes of a molecular clone of HIV-1 can now be analyzed
after passage in nonhuman primate species as the SHIVsbg replicates efficiently. The SHIVsbg-macaque model is an
important step in the development of a readily available animal model for HIV-1 vaccine studies. q 1996 Academic Press, Inc.
INTRODUCTION the DH12 isolate of HIV-1 may be more virulent than
those tested up to now (Shibata et al., 1995). Pig-tail
Since the description of the acquired immune defi- macaques (Macaca nemestrina) are only poorly sensitive
ciency syndrome (Gottlieb et al., 1981) and the identifica- to HIV-1 infection (Agy et al., 1992) and have not even
tion of human immunodeficiency virus (HIV) as the etio- been used as models for vaccine studies. Unfortunately
logical agent (Barre´-Sinoussi et al., 1983), great progress the endangered nature of chimpanzees and the limited
has been made in understanding lentiviral pathogenesis supply of the pig-tail macaque further restrict the utility
(Fauci et al., 1993). However, our knowledge about this of these primates as experimental models for HIV-1 infec-
immunodeficiency disease is still incomplete and the tion.
contribution of virus and host factors to HIV virulence is A number of pathogenic and nonpathogenic clones of
ill-defined. The ideal animal model of HIV-1 infection SIV have been characterized in the common species of
does not exist and this is a limitation on achieving the macaque monkeys (Marthas et al., 1989; Kestler et al.,
ultimate goals of successful prophylaxis and therapy. 1990; Johnson et al., 1991; Rud et al., 1994). The attenua-
Due to the very narrow host range of the virus, small tion of pathogenic SIVs has helped to define the role of
laboratory animals are poorly susceptible to HIV infection specific primate lentivirus genes in viral pathogenesis
(Morrow et al., 1987) including those transgenic animals (Kestler et al., 1991, Lang et al., 1993; Gibbs et al., 1995)
which express the virus receptor (Lores et al., 1992; Dunn and the SIV-macaque model has also allowed the evalua-
et al., 1995). tion of a range of vaccine strategies (Stott, 1994). Al-
Despite the inherent drawbacks of using nonhuman though the SIVs are closely related to HIV-2 (Clavel et
primate models, the infection of chimpanzees (Pan trog- al., 1986) and the disease induced in macaques is very
lodytes) with HIV (Fultz, 1993) and macaques (Macaca similar to AIDS in man, it is the difference in the structure
species) with simian immunodeficiency viruses (SIV) has and biological properties between the envelope glyco-
greatly facilitated our understanding of HIV infection of proteins of SIVmac and HIV-1 which is most significant
human (Desrosiers, 1991). Chimpanzees are consistently (Shioda et al., 1991; Mori et al., 1992; Robert-Guroff et
susceptible to HIV-1 infection (Fultz et al., 1986). How- al., 1992; Hirsch et al., 1994; Kirchhoff et al., 1994). The
ever, viral loads are much reduced (ten Haaft et al., 1995) variability and immunogenicity of the V3 loop of HIV-1 is
relative to man and disease is rarely provoked although much greater than the homologous region of SIVmac
(Javaherian et al., 1992; Almond et al., 1993). This struc-
ture is an important target for HIV-1 neutralizing antibod-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 88 56 63 03. ies (Emini et al., 1992), which has lead to interest in
351
0042-6822/96 $18.00
Copyright q 1996 by Academic Press, Inc.
All rights of reproduction in any form reserved.
AID VY 8117 / 6a1e$$$$$1 08-16-96 16:45:30 vira AP: Virology
352 DUNN ET AL.
the envelope glycoprotein as a component of subunit Cell cultures
vaccines.
The continuous human cell line CEMx174 is a B/T cellChimeric primate lentiviruses (SHIV) consisting of HIV-
hybrid and the MT-4 cell line is also of human lymphoid1 envelope and regulatory genes with the LTRs and gag
origin. Both lines are maintained in RPMI medium at 377and pol genes from SIVmac have been constructed in
in 5% CO2 and supplemented with 10% decomplementedseveral laboratories (Shibata et al., 1991; Li et al., 1992;
fetal calf serum (Gibco, United Kingdom) and 2 mM Gluta-Luciw et al., 1995; Mamounas et al., 1995). This approach
max (Gibco, United Kingdom). Human and macaque pe-in vivo should allow the study of HIV-1 envelope subunit
ripheral blood mononuclear cells (PBMC) were isolatedvaccines in readily available species of monkey as well
on a Ficoll–Hypaque gradient (Eurobio, France), spec.as the study of discrete HIV-1 genes in lentiviral patho-
grav., 1.077. After washing in phosphate-buffered salinegenesis (Shibata and Adachi, 1992). Just as low virus load
(PBS), the PBMC were cultivated in the above mediumand lack of virulence must be considered deficiencies
and stimulated with phytohemagglutinin (PHA; Murex Di-in the chimpanzee–HIV-1 model, similar problems have
agnostics Ltd., United Kingdom) at 2 mg/ml for 2 days,been encountered with the macaque–SHIV models (Iga-
after which the PHA was removed by washing. Recombi-rashi et al., 1994; Li et al., 1995). Up to now, evidence
nant human interleukin-2 (Boehringer, Germany) at 20 IUfor pathogenic effects such as immunodeficiency or even
per milliliter was added to all cultures of PBMC.CD4 lymphopenia induced by a molecular clone of SHIV-
env have not been reported, even for SHIV SF33, which Construction of chimeric primate lentivirus, SHIVsbg
appears to replicate very efficiently in rhesus monkeys
(Luciw et al., 1995). The genome of SHIVsbg was reconstituted in vitro by
ligation of the 5* and 3* half genomes after SphI diges-We describe the construction of SHIVsbg from the SIV-
mac239 and HIV-1 Lai molecular clones and the infection tion. The strategy used to obtain the two half-genomes
is derived from that described by Li et al. (1992) so onlyof Indian and Chinese subspecies of rhesus macaque
and cynomolgus monkeys. Cell-associated viral loads the differences will be indicated here.
The parent plasmids were p239SpSp5* and p239SpE3*are similar to those observed in HIV-1 infection of human
and the immune response to HIV-1 envelope glycopro- (Kestler et al., 1990) for SIVmac239 and pJ19-6 and pJ19-
13 (Alizon et al., 1984) for HIV-1 Lai, formerly called LAVteins is rapid and strong. Lymphadenopathy and a deple-
tion of CD4 lymphocyte numbers in peripheral blood are (Wain-Hobson et al., 1985, 1991). The latter was originally
replicated only on human PBMC prior to cloning andadditional indicators of a high level of replication of
SHIVsbg in macaques. This model is of fundamental in- contains many point mutations compared to the HXBc2
molecular clone of HIV-1 used by Li et al. (1992) for theterest in studies of pathogenesis and an important ad-
vance for the testing of HIV-1 candidate vaccines for construction of SHIV-4. The 5* half-genome was modified
as described for SHIV-4 and was cloned into plasmidhuman.
pBS (Stratagene, CA) and designated pTG4036. How-
ever, the 3* half-genome of SHIVsbg differs from SHIV-4MATERIALS AND METHODS
in several respects other than the origin of the HIV-1
Animals
genes incorporated into SIVmac239.
The natural HIV-1 tat splice acceptor site was con-Three monkeys of each of the Indian and Chinese
subspecies of rhesus macaque (Macaca mulatta) and served upstream of the HIV-1 tat coding sequence.
Therefore the EcoRI restriction site at position 5289 inthree cynomolgus monkeys (Macaca fascicularis) were
each infected with 440 TCID50 of the SHIVsbg by the the pJ19-13 fragment was mutated to a SphI restriction
site. These changes allow the recovery of the 3* vpr SIVintravenous route using the saphenous vein. The rhesus
monkeys were 2- to 3-year-old juveniles and the cyno- sequence and a stop codon for the vpr coding sequence
was engineered (Fig. 1). The resulting SphI-KpnI (5289–molgus monkeys were young adults. All animals tested
seronegative for type D simian retroviruses, simian T- 5889) fragment was used in the SHIV construct. An addi-
tional SmaI site was introduced upstream of the gp120–cell leukemia virus type 1, SIVmac, and herpes B prior to
the commencement of the experimental protocol. Blood gp41 cleavage site by site-directed mutagenesis of nu-
cleotides 7277–7282 (Wain-Hobson et al., 1985). Thissampling and lymph node biopsies of monkeys were
performed under sedation with ketamine (10 mg/kg, Imal- mutation results in a Lys to Arg change in the sequence
VAPTKA of gp120 of HIV-1 Lai and was introduced togene, Me´rieux) and atropine (0.05 mg/kg). The right ingui-
nal lymph node was chosen for biopsy in all cases and allow the exchange of different gp120 coding sequences
by using the KpnI–SmaI restriction fragment (positionsthe left node was taken from the three animals biopsied
a second time. Animals were bled prior to and on the 5889–7282).
The SIV nef gene and 3* LTR were derived fromday of infection to establish hematological values and
subsequently bled on Days 4, 7, 11, 14, 21, 28, 42, 70, p239SpE3* in which the premature stop codon TAA in the
SIVmac239 nef gene (Kestler et al., 1990) was mutated to112, 154, and 210.
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FIG. 1. General organization of the 3* half-genome of the SHIVsbg. (A) Schematique representation of the 3* half-genome of SHIVsbg. Gray boxes
represent SIVmac239 sequences; the white box comprises HIV-1 Lai sequences coding for tat, rev, vpu, and env. The first splice acceptor site of
tat (S. A. tat) is marked by a vertical dotted line. The major restriction sites are localized by vertical bars. The arrows represent open reading frames
of env, nef, and the end of vpr. (B) Sequence of the 5* junction between SIVmac239 and HIV-1 regions. (C) Sequences surrounding the SmaI site
introducted by site-directed mutagenesis. The mutated nucleotides are in boldface. (D) Sequences of the 3* junction between HIV-1 Lai and
SIVmac239 regions. The A nucleotide located 05 from the start codon of the SIVmac239 nef gene is deleted in the SHIVsbg sequence. For (B),
(C), and (D) restriction sites are underlined, start codons are marked by an arrow, and stop codons are boxed. The sequences of HIV-1 Lai and
SIVmac239 are noted following the numeration of Wain-Hobson et al. (1985) and Regier and Desrosiers (1990), respectively.
GAA in order to ensure the presence of a functional Nef Infection of human and macaque cells by SHIVsbg
protein from the start of SHIVsbg infection. The plasmid Human and macaque PBMC, CEMx174 cells, and MT-
containing the 3* half of the SHIV genome was desig- 4 cells were infected with SHIVsbg and its parental vi-
nated pTG5043. ruses. A dose of 300 TCID50 was used per 10
6 primary
cells or per 31 105 CEMx174 and MT4 cells. The infectiv-
Preparation of stock of SHIVsbg
ity of the stocks of the parental viruses was determined
on CEMx174 cells as for the stock of SHIVsbg. FollowingThe ligation products of the two half-genomes were
a 1-hr adsorption at 377, the cells were washed in culturetransfected into the CEMx174 cell line by electroporation
medium and plated. Cultures were checked for the ap-using the voltage and capacitance recommended for
pearance of a cytopathic effect and supernatants werelymphoid cells (Easyject Plus, Eurogentec, Belgium). A
checked for RT activity twice weekly.total of 10 mg of viral cDNA was mixed with 10 1 106
cells suspended in 800 ml of RPMI culture medium and
Radioimmunoprecipitation analysisa potential difference of 280 V was applied across the
chamber with a capacitance of 1500 mF. Cells were sub- SHIVsbg and SIVmac251BK28, a clone having 98% se-
quence homology with SIVmac239 (Regier and Desro-sequently cultured at 106 cells/ml and supernatants were
assayed for the presence of reverse transcriptase as siers, 1990), were grown in CEMx174 cells in the pres-
ence of 35S-labeled cysteine and methionine as de-previously described (Moog et al., 1994).
The presence of infectious virus particles was demon- scribed previously (Liska et al., 1994). Uninfected
CEMx174 cells were used as a negative control andstrated by the passage of this supernatant on PBMC
isolated from a healthy rhesus macaque. Once these SHIVsbg02, which is similar to SHIVsbg except for the
absence of the tat splice acceptor site, was also in-primary cell cultures became positive by the RT assay,
supernatants constituting the virus stocks for animal in- cluded. Viral proteins in cell-free supernatants and those
associated with cell pellets were immunoprecipitated byfections were collected and stored daily. Viral infectivity
was assayed by titration on CEMx174 cells using the sera from SIVmac-infected macaques and an HIV-1-in-
fected human, chosen for its high reactivity with HIV-end-point dilution method. Individual wells were deter-
mined to be positive for viral replication by the identifica- 1 glycoproteins relative to other proteins. Analysis by
electrophoresis on a 12.5% sodium dodecyl sulfate–poly-tion of RT activity 14 days postinfection. Titers were sub-
sequently calculated by the method of Reed and Muench acrylamide gel allowed the identification of SIVmac or
HIV-1 glycoprotein and the full-length SIV Nef protein.(1938).
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FIG. 2. Replication of SHIVsbg and its parental viruses on human lymphoid cell lines and human and macaque PBMC. 106 PBMC or 3 1 105
CEMx174 or MT4 cells were infected with 300TCID50 of SHIVsbg, HIV1 Lai, or SIVmac239. After a 1-hr adsorption, free virus was washed out, cells
were resuspended at a density of 106 PBMC/ml or 1.5 1 105 CEMx174 or MT4/ml and distributed in culture plates. Virus production was monitored
twice weekly by RT assays done on culture supernatants.
Hematology and immunophenotyping of lymphocytes by cocultivation of 2.5 1 106-, 106-, and 5-fold serial
dilutions of 0.5 1 106 primary cells with 1.5 1 105Standard hematological parameters of red and white
CEMx174 cells in 24-well plates. These coculturesblood cell populations were measured on a Coulter
were treated twice weekly, once to change mediumcounter apparatus. The CD4 and CD8 phenotypes of lym-
and once to divide cells, and from Day 7 were checkedphocytes from whole blood were determined by immuno-
for RT activity on each occasion. Rising levels of RTlabeling and flow cytometry. Whole blood collected in
activity were taken as evidence of viral replication inEDTA tubes was incubated with either the OKT4 mono-
a given coculture and then the number of infectedclonal antibody (mAb; OrthoDiagnostic Systems, Raritan,
cells was calculated per 106 PBMC. Similarly the freeNJ) coupled to phycoerythrin or the fluorescein-conju-
virus load in plasma was determined by the isolationgated Leu2a mAb (Becton Dickinson, France). These
of virus using CEMx174 cells incubated with 2-foldmAbs recognize human CD4 and CD8 proteins, respec-
limiting dilutions of plasma. All these cultures weretively, and cross-react with the homologous macaque
performed in duplicate.antigens. After a 15-min incubation, the red cells were
Cocultures of CD8 lymphocyte-depleted macaquelysed (red cell lysis buffer, Becton Dickinson), washed in
PBMC and CEMx174 cells were also performed. TheFacsFlow (Becton Dickinson), and resuspended in 2%
depletion of macaque CD8-positive lymphocytes by im-paraformaldehyde in PBS. The fluorescence associated
munomagnetic bead selection (Dynabeads M450, Dynal,with the lymphocyte subpopulation using the respective
Norway) was carried out following the protocol of themAbs was analyzed by a FACScan fluorescence-acti-
manufacturer. After a 30-min incubation at 47 with a bead-vated cell sorter using Lysis II software (Becton Dickin-
to-cell ratio of 10, the CD8 cells, rosetted by beads, wereson).
depleted using a magnet. The remaining cells were then
Quantitation of virus load cocultivated.
Biopsied lymph node tissue was dissociated by cuttingThe virus load associated with macaque PBMC iso-
lated on a Ficoll – Hypaque gradient was determined with scissors and vigorous pipetting. After being filtered
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through gauze to ensure a single-cell suspension, cells
were pelleted and washed twice in PBS before being
counted and cocultured in limiting dilutions as described
above for PBMC.
Serology
Antibodies to HIV present in the serum of infected
macaques were analyzed by a commercial ELISA test
(Murex, Wellcome). This kit allows the detection of anti-
bodies to HIV-1 and HIV-2 envelope and core peptides.
Western blots using HIV-1 antigens (New Lav Blot I, Diag-
nostics Pasteur) determined the specificity of antibody
against the relevant glycoproteins. Both these kits were
used according to the protocols of the respective manu-
facturers.
RESULTS
Characterization of SHIVsbg
Following the transfection of the SHIVsbg viral cDNA
into CEMx174 cells, RT activity in culture supernatants
FIG. 3. Demonstration by radioimmunoprecipitation assay of thewas detected after 12 days. These supernatants were
presence of HIV-1 envelope glycoprotein in chimeric stock virus grown
stored and used to infect mitogen-stimulated macaque on CEMx174 cells and the absence of SIV envelope glycoprotein. Nine
and human PBMC as well as the CEMx174 and MT-4 days after infection with SHIVsbg, SHIVsbg02, or SIVmac (see Materials
and Methods for characteristics) , cells were metabolically labeledcell lines. A comparison of viral replication demonstrated
for 18 hr with [35S]cysteine–methionine. The cells and cell-free virusthat the SHIVsbg multiplies 10 times more efficiently on
collected from culture supernatant by ultracentrifugation were lysedthe human primary cells relative to the macaque cells
in dissociating buffer and subjected to immunoprecipitation with SIV-
but no cytopathic effect is observed (Fig. 2). positive macaque serum. A fraction of virus lysate was immunoprecipi-
Both the parental viruses of SHIVsbg, SIVmac239 tated with HIV1-positive human serum chosen as the HIV1 antibodies
were mainly directed against the glycoproteins. Proteins of the immuneand HIV-1 Lai, replicate more efficiently on CEMx174
complexes were resolved by SDS–polyacrylamide gel electrophoresisthan the chimeric virus (Fig. 2), although SHIVsbg mul-
and autoradiography. Control, refers to uninfected cells labeled andtiplies better on the MT-4 cell line. The replication of
immunoprecipitated in parallel. Unmarked lanes were loaded with mo-
SHIVsbg relative to its parental viruses is dependent lecular mass markers; masses are indicated in kilodaltons on the left
on cell type. side.
Sera from an HIV-1 seropositive individual, but not sera
from SIVmac-infected macaques, were able to immuno-
these macaques have not shown systemic signs ofprecipitate the envelope glycoprotein from the SHIVsbg
illness and no cutaneous exantem has been observed.(Fig. 3), demonstrating the presence of the HIV-1 enve-
Immunophenotyping of lymphocytes from peripherallope and the absence of the SIV envelope. Analysis of
whole blood to determine the CD4/CD8 ratio demon-the immunoprecipitates from the cellular fractions dem-
strated inversion begining at 3 weeks postinfectiononstrates the presence of the Nef protein (34 kDa) of
which has persisted in certain animals (Fig. 4a). AnSIVmac239, which is larger than that of SIVmac251, in
analysis of the absolute numbers of CD4 lymphocytescells infected by the SHIVsbg.
shows that a CD4 lymphopenia is concurrent with theThe stock virus used to inoculate animals was grown
CD4/CD8 inversion (Fig. 4b). Although there may beon macaque PBMC. A titration of infectivity on CEMx174
some recovery of CD4 cell numbers, preinfection levelscells demonstrated a titer of 4400 TCID50/ml which repre-
have not been fully attained except in the case of onesents 16.4 ng/ml of SIVmac p27 core protein as deter-
cynomolgus monkey. This pattern of CD4 lymphopeniamined using the Coulter SIV Core Antigen Assay (Coulter
is similar in the three groups of animals and representsImmunology, Hialeah, FL).
about a 50% depletion despite the variability in abso-
lute numbers between individuals.Clinical examination and immunophenotyping of
lymphocytes
Serology
Clinical examinations revealed persistent lymphade-
nopathy of axillary and inguinal lymph nodes which All animals seroconverted to HIV proteins, as detected
by ELISA, 2–4 weeks postinfection and the titer of anti-was apparent from 2 weeks postinfection. Otherwise,
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FIG. 4. Inversion of CD4/CD8 ratios (a) and absolute CD4 lymphocyte depletion (b) in peripheral whole blood of SHIVsbg-infected macaques. For
more details, see Materials and Methods.
body continued to rise (Fig. 5). Antibody titers are approx- recognize the glycoproteins of HIV-1 (Fig. 6). Reactivity
is strongest against gp160 and gp120 but difficult to dis-imately one log greater in the Indian rhesus macaques
than in the Chinese rhesus and cynomolgus monkeys. tinguish in certain animals for gp41. The band for p24
HIV-1 represents a cross reaction of antibodies normallyWestern blots performed 30 weeks postinfection show
antibodies in the serum of all these macaques which recognizing p27 of SIVmac.
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in all animals during the acute phase of the infection
and virus has been isolated at all attempts during the
chronic phase although only after CD8 depletion in
certain cases (Table 1). The number of infected PBMC
peaked at 2 – 3 weeks postinfection with up to one cell
in 30 infected. Confirmation of elevated virus loads
has been obtained from biopsied peripheral lymph
nodes (Table 2). After the initial immune response,
there is a sharp decline in the number of infected
cells in both lymph node and peripheral blood. The
dynamics of viral replication are closely paralled in
the three groups of animals investigated.
Infectious free virus has been isolated from the plasma
of all animals during the acute phase with the lowest
titers being observed in the Chinese macaques and the
most uniform load being identified in the cynomolgus
monkeys (Table 3). Titers ranged between 8 and 266
TCID50/ml of plasma. Due to the dilution of the plasma
FIG. 5. Rising serum antibody titers in SHIVsbg-infected macaques.
The temporal antibody response was determined from the day of infec-
FIG. 6. Detection of HIV1 glycoprotein-specific antibodies intion and later, using a commercial HIV ELISA kit. Antibody titers are
SHIVsbg-infected macaques. HIV1 commercial Western blots werethe reciprocals of the highest dilutions of sera giving an optical density
probed with sera taken 30 weeks postinfection. The presence of anti-of 0.1 above the cut-off values.
bodies against HIV-1 glycoproteins is confirmed; antibodies against
SIVmac p27 protein cross-reacting with HIV1 p24 are also detected.
The positions of the HIV1 envelope (gp160, gp120 and pg41) and capsid
Virus load (p24) proteins are indicated on the right. Numbers above the lanes
refer to the infected macaques: Chinese rhesus macaques, 133, 137,
Coculture of PBMC following limiting dilution with 141; Indian rhesus macaques, 200, 209, 212; cynomolgus macaques,
1926, 5546, 7105.CEMx174 indicator cells has revealed high virus loads
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TABLE 1
Cell-Associated Virus Load Expressed as Number of Cells Infected per Million PBMC; Limiting Dilutions of PBMC
Were Cocultured with CEM 1 174 Cells and Virus Replication Was Detected by RT Activity
Cells infected per 106 PBMC
Weeks postinfection
Species No. 1 2 3 4 6 10a 16 a 22b 30b
Chinese rhesus macaque 133 250 6250 150 250 250 2/10 1/2 2 1
137 50 3750 30 50 6 50/10 0/2 1 1
141 30 3750 50 150 6 1/10 0/2 1 1
Indian rhesus macaque 200 150 1250 250 150 30 10/10 0/10 1 2
209 50 18750 150 30 10 1/2 1/2 2 1
212 750 6250 31250 50 30 10/50 10/10 10 2
Cynomolgus macaque 1926 30 31250 150 6 50 2/2 0/1 2 1
5546 650 18750 750 150 150 2/10 10/50 2 10
7105 50 6250 250 50 10 10/1250 0/2 1 0
a The second figure in each column is the coculture result following depletion of CD8 lymphocytes from macaque PBMC.
b Cocultures were performed only after CD8 lymphocyte depletion from macaque PBMC.
to avoid a toxic effect on the CEMx174 cells, the limit of tics predicted by those of the parental viruses. In addi-
detection of this technique is 4 TCID50/ml. tion, the high viral load and CD4 lymphopenia observed
in infected Macaca species is not anticipated from the
DISCUSSION level of viral replication in macaque PBMC in vitro.
Previous studies have demonstrated that chimeric pri-The construction of an infectious recombinant virus
mate lentiviruses of SIV and HIV genes are infectious forconsisting of genes from HIV-1 Lai and SIVmac239
macaque monkeys and viral replication can provoke anshould allow an analysis of the function of discrete genes
immune response (Li et al., 1992, 1995; Sakuragi et al.,of HIV-1 in nonhuman primates. Such a virus might also
1992; Igarashi et al., 1994; Letvin et al., 1995; Voss et al.,be used to challenge monkeys immunized by HIV-1 sub-
1995). However, with the exception of SHIV SF33 (Luciwunit vaccines. The SHIVsbg is a chimeric primate lentivi-
et al., 1995), chimeric virus has not been consistentlyrus which does not have in vitro replication characteris-
isolated from infected macaque PBMC and detailed
quantifications of virus loads have not been established.
The SHIVsbg cell-associated loads described here areTABLE 2
comparable with those determined by Luciw et al. (1995)Virus Load in Lymph Nodes Expressed as Number of Cells Infected
for SHIV SF33 and for symptomatic HIV-1 infection ofper 106 Cells in a Single-Cell Suspension Prepared from Lymph Node
Biopsies, Limiting Dilutions of Cells Were Cocultured with CEM 1 human (Daar et al., 1991). Furthermore we have identified
174 Cells and Virus Replication Was Detected by RT Activity CD4 lymphocyte depletion and lymphadenopathy which
is corroborative evidence for a high level of viral replica-
No. of lymph node cells
tion. These parameters represent markers of infectioninfected/106
other than viral load which may be followed in the evalua-
Weeks postinfection tion of vaccines in this model. Animals infected by our
SHIVsbg virus stock do not produce antibodies to SIVSpecies No. 2 3 6 10
glycoproteins and the phenotype of the virus isolated
Chinese rhesus macaque 133 18750 ND ND 10 from animals on CEMx174 cells has remained noncyto-
137 ND 3750 ND ND pathogenic. Glycoproteins of SIVmac have not been re-
141 ND ND 250 ND
vealed by RIP assay using chimeric stock virus replicat-
Indian rhesus macaque 200 31250 ND ND 10 ing on CEMx174 cells. Therefore our observations are
209 ND 3250 ND ND unlikely to be due to a contamination of the virus stock
212 ND ND 150 ND
with SIVmac. Routine serological screening of these ani-
Cynomolgus macaque 1926 ND 1250 ND 50 mals has not identified evidence of other simian retrovi-
5546 31250 ND ND ND ruses which might complement SHIVsbg replication.
7105 ND ND 250 ND
Several possibilities exist for the apparently higher vi-
Note. ND, not determined. ral load we describe for SHIVsbg relative to that of SHIV-
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TABLE 3
Infectious Cell-Free Virus Load in Plasma of Monkeys Infected by SHIVsbg; Twofold Serial Dilutions of Plasma Derived
from Heparinized Whole Blood Were Added to CEM 1 174 Cells and Virus Replication Was Detected by RT Activity
TCID50 /ml of plasma
Weeks postinfection
Species No. 1 2 3 4 6 10
Chinese rhesus macaque 133 0 266 0 0 0 0
137 11 16 0 0 0 0
141 0 16 0 0 0 0
Indian rhesus macaque 200 0 15 8 0 0 0
209 0 0 22 0 0 0
212 0 52 266 0 0 0
Cynomolgus macaque 1926 33 266 8 0 0 0
5546 0 133 88 0 0 0
7105 0 266 133 0 0 0
4 (Li et al., 1992), which has a similar construction. The rhesus monkeys of different origins may vary in their
sensitivity to infection by a stock of SIVmac251 (LewisHXBc2 molecular clone of HIV-1 used for SHIV-4 differs
from Lai as the former was adapted to lymphoid cell lines et al., 1994) but despite the different species and subspe-
cies we have studied, we have demonstrated uniformprior to cloning. SHIV-4 does not have an open reading
frame for the vpu gene (Li et al., 1992) and this has a viral loads and CD4 cell depletions although there were
higher antibody titers in the Indian rhesus macaques.definite effect on the ease of virus isolation and viral
load (Li et al., 1995). The presence of an intact tat splice That SHIVsbg can infect those species of monkey which
are commercially available is an important practical con-acceptor site and mutations in the env gene to create a
cassette to allow the insertion of other HIV-1 env genes sideration for an animal model for HIV-1 vaccine studies.
All the macaques inoculated with SHIVsbg have devel-are additional changes to SHIVsbg which might have an
effect on in vivo replication. Unlike other chimeric viruses oped a humoral immune response to the proteins and
glycoproteins of HIV-1. However, there is a 1-week delay(Li et al., 1992; Sakuragi et al., 1992 Luciw et al., 1995), the
SHIVsbg replicated less well than the parental viruses on in the time of seroconversion between the rhesus mon-
keys and the cynomolgus monkeys and this may explainmacaque PBMC and CEMx174 cells and is noncytopath-
ogenic in vitro. This is a further example of the lack of why a greater quantity of infectious virus is found in the
plasma of the latter. The rising titers of antibody implycorrelation between in vitro and in vivo phenotypes of
primate lentiviruses (Marthas et al., 1989). sustained viral replication despite simultaneously falling
viral loads in blood and tissue as determined by cocul-Comparisons can also be made between the infection
of macaques with SIVmac239 and SHIVsbg. The viral ture. Thirty weeks after infection, an analysis by Western
blot indicates that the animals have antibodies in serumloads in the acute phase of both infections are similar
but once an immune response is established, cell-asso- which recognize the gp120 and gp160 of HIV-1 although
the presence of antibodies to gp41 is more variable. Forciated viral loads are up to 1000 times reduced for
SHIVsbg compared to SIVmac239. Numerous studies the macaque-SHIV model to be of use in studying the
role of the immune response to HIV-1 glycoprotein inhave testified to the very high virus load maintained dur-
ing SIVmac239 infection (Kestler et al., 1991; Sharma et pathogenesis, this strong humoral response is indispen-
sible. Further studies to exploit this model are underwayal., 1992; Marthas et al., 1993; Joag et al., 1994; Lohman
et al., 1994; Lang et al., 1993; Gibbs et al., 1995; Hoch et to determine the existence and possible role of both
neutralizing antibodies and viral variants in the pathogen-al., 1995; Luciw et al., 1995). This indicates that the env,
rev, and tat genes of SIVmac239 could be important viral esis of SHIVsbg infection.
To our knowledge this is the first time that a lentiviraldeterminants for such an elevated viral load relative to
SHIVsbg in the chronic phase of the infection. molecular clone with an HIV-1 envelope has replicated
with such efficiency and caused CD4 lymphopenia inThere has always been anecdotal evidence that Indian
rhesus monkeys were more sensitive to pathogenic SIV nonhuman primates although recent reports have estab-
lished that the passage of poorly replicating SHIV caninfection than those of Chinese origin. Joag et al. (1994)
have confirmed that Indian rhesus monkeys infected by considerably increase virulence in pig-tail macaques
(Narayan et al., 1995). Obviously the use of a chimericSIVmac239 have viral loads which are higher than those
of Chinese rhesus monkeys by a factor of 10–100. Even virus with an envelope from HIV-1 maintained in PBMC
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potential model for acquired immunodeficiency syndrome. J. Virol.undermines the use of this virus for directly evaluating
58, 116–124.HIV-1 vaccines composed of envelope glycoprotein sub-
Gibbs, J. S., Lackner, A. A., Lang, S. M., Simon, M. A., Sehgal, P. K.,units from certain primary isolates. However, there is Daniel, M. D., and Desrosiers, R. C. (1995). Progression to AIDS in
fundamental interest in the study of how the env and vpu the absence of a gene for vpr and vpx. J. Virol. 69, 2378–2383.
genes of HIV-1 Lai might mutate in order to adapt to in Gottlieb, M. S., Schroff, R., Schanker, H. M., Weisman, J. D., Fan, P. T.,
Wolf, R. A., and Saxon, A. (1981). Pneumocystis carnii pneumoniavivo replication and how the insertion of other env genes
and mucosal candiasis in previously healthy homosexual men. N.from primary isolates of HIV-1 might affect the biological
Engl. J. Med. 305, 1425–1431.characteristics of the virus. A high viral load and CD4
Hirsch, M. V., Zack, P. M., Vogel, P., and Johnson, P. R. (1992) Simian
lymphopenia have been demonstrated in these macaque immunodeficiency virus infection of macaques: end-stage disease is
monkeys infected by SHIVsbg and these are essential characterised by widespread distribution of proviral DNA in tissues. J.
Infect. Dis. 163, 976–988.prerequisites for a pathogenic outcome.
Hirsch, V. M., Martin, J. E., Dapolito, G., Elkins, W. R., London, W. T.,
Goldstein, S., and Johnson, P. R. (1994). Spontaneous substitutions
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